Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. The company is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone856-697-1441
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$65.86 million
Profitability
Miscellaneous
Employees189
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable
Teligent (NASDAQ:TLGT) Frequently Asked Questions
What is Teligent's stock symbol?
Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How were Teligent's earnings last quarter?
Teligent Inc (NASDAQ:TLGT) released its earnings results on Monday, November, 4th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The firm had revenue of $18.47 million for the quarter, compared to analyst estimates of $19.82 million. Teligent had a negative return on equity of 232.25% and a negative net margin of 51.29%. View Teligent's Earnings History.
When is Teligent's next earnings date?
What is the consensus analysts' recommendation for Teligent?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teligent in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teligent.
Has Teligent been receiving favorable news coverage?
Media coverage about TLGT stock has been trending positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teligent earned a news impact score of 2.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Teligent.
Are investors shorting Teligent?
Teligent saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 7,230,000 shares, a drop of 10.1% from the December 15th total of 8,040,000 shares. Based on an average daily volume of 363,900 shares, the days-to-cover ratio is presently 19.9 days. Currently, 16.6% of the company's stock are short sold. View Teligent's Current Options Chain.
Who are some of Teligent's key competitors?
Some companies that are related to Teligent include Enlivex Therapeutics (ENLV), Catalyst Biosciences (CBIO), Elite Pharmaceuticals (ELTP), ESSA Pharma (EPIX), Catabasis Pharmaceuticals (CATB), IMMUTEP LTD/S (IMMP), Aclaris Therapeutics (ACRS), Trevena (TRVN), Eyenovia (EYEN), CTI BioPharma (CTIC), Oncolytics Biotech (ONCY), Trillium Therapeutics (TRIL), Cumberland Pharmaceuticals (CPIX), Neos Therapeutics (NEOS) and VERONA PHARMA P/S (VRNA).
What other stocks do shareholders of Teligent own?
Who are Teligent's key executives?
Teligent's management team includes the folowing people:
- Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 44)
- Mr. Stephen Richardson, Chief Scientific Officer (Age 53)
- Mr. Martin Wilson, Gen. Counsel (Age 42)
- Mr. Damian Finio, Corp. Sec. & CFO (Age 49)
- Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 50)
Who are Teligent's major shareholders?
Teligent's stock is owned by a number of of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (3.90%) and Wedbush Securities Inc. (0.21%). Company insiders that own Teligent stock include Bhaskar Chaudhuri, Carole Ben-Maimon, Damian Finio, James C Gale, Jason Grenfell-Gardner and Stephen Richardson. View Institutional Ownership Trends for Teligent.
Which major investors are selling Teligent stock?
Which major investors are buying Teligent stock?
TLGT stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Teligent stock in the last two years include Bhaskar Chaudhuri, Carole Ben-Maimon, Damian Finio, James C Gale, Jason Grenfell-Gardner and Stephen Richardson. View Insider Buying and Selling for Teligent.
How do I buy shares of Teligent?
Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Teligent's stock price today?
One share of TLGT stock can currently be purchased for approximately $0.40.
How big of a company is Teligent?
Teligent has a market capitalization of $21.69 million and generates $65.86 million in revenue each year. The company earns $-36,260,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Teligent employs 189 workers across the globe.View Additional Information About Teligent.
What is Teligent's official website?
How can I contact Teligent?
Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]
MarketBeat Community Rating for Teligent (NASDAQ TLGT)
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
